Elizabeth Black-schaffer, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40 Crosby St, Milford, NH 03055 Phone: 603-673-7061 |
Kathleen L Doyle, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 43 Ledgewood Dr, Milford, NH 03055 Phone: 603-672-5037 |
Sara H Sowder Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 71 Elm St, Milford, NH 03055 Phone: 937-216-0590 |
Catherine Walencis, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 29 Birchwood Dr, Milford, NH 03055 Phone: 603-809-3380 |
Janet Marie Zalenski, MS, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 14 Merrimack St, 240, Milford, NH 03055 Phone: 603-249-5757 |
Katie Maureen Leduc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 40 Crosby St, Milford, NH 03055 Phone: 603-673-7061 |
News Archive
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research.
Global Health Partner has inaugurated its own clinic for the treatment of obesity and metabolic disorders in Prague and the first obesity operations have been performed. The Czech Republic has a well insured population where patient flows are directed to clinics with strong medical results. "The Czech Republic is one of the markets that we have identified as interesting.
Nurses have a responsibility to respect and support patients who use cannabis for medicinal purposes, but must stay within the law and follow professional guidance at all times, according to a research review in the September issue of the Journal of Clinical Nursing.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has entered into a Research, Option and License Agreement ("License Agreement") and a Share Purchase Agreement with One Way Liver Genomics S.L., for the development of a non-invasive, blood-based companion diagnostic tool.
› Verified 7 days ago